Serum Hepcidin Immunoassay - Laboratory to Marketplace
Status: | Recruiting |
---|---|
Conditions: | Anemia |
Therapuetic Areas: | Hematology |
Healthy: | No |
Age Range: | 11 - Any |
Updated: | 4/17/2018 |
Start Date: | June 30, 2016 |
End Date: | February 2019 |
Contact: | Katrina Daigle |
Email: | katrina.daigle@childrens.harvard.edu |
Phone: | 617-355-2668 |
Evaluation of the Intrinsic Hepcidin IDx™ Test to Detect Iron Deficiency and Predict Response to Oral Iron Therapy in Adolescents and Young Adults
This is a single center, prospective, observational study to demonstrate the clinical
validity of the Intrinsic LifeSciences (ILS) Intrinsic Hepcidin IDx™ Test in the diagnosis
and management of iron deficiency (ID) in adolescents and young adults. This test is
considered non-significant risk.
validity of the Intrinsic LifeSciences (ILS) Intrinsic Hepcidin IDx™ Test in the diagnosis
and management of iron deficiency (ID) in adolescents and young adults. This test is
considered non-significant risk.
Inclusion Criteria:
- Age at least 11 years
- Subjects must give informed assent/ consent prior to the blood draw. Subjects that are
minors (<18 years) must have a parent or guardian give informed consent and the
subject must give assent to participate in the study.
- Willing to comply with all oral iron supplementation and follow up visits if they move
to the Observation of Treatment Phase.
- Able to communicate in English.
Exclusion Criteria:
- Acute febrile illness (Temp ≥100.4°F (38°C), or acute otitis media, gastroenteritis,
pharyngitis or other URI, within the previous one week.
- History of known hemoglobinopathy (e.g., thalassemia trait or sickle cell)
- Any parenteral iron received in the 30 days prior to enrollment.
- Presently taking oral iron supplements (except for iron as part of multivitamin or
oral contraceptive pill) or has taken it in the 30 days prior to enrollment.
- An allergy or hypersensitivity to oral iron sulfate.
- Has received a blood transfusion in the 90 days prior to enrollment.
- Any investigational drug use in the 30 days prior to enrollment.
- Any known malignancy.
- Receiving dialysis.
- Known to be pregnant or currently breast-feeding.
- Any lab abnormality, medical condition, or psychiatric disorder which in the opinion
of the investigator would put the subject's disease management at risk or may result
in the subject being unable to comply with study requirements.
We found this trial at
1
site
300 Longwood Ave
Boston, Massachusetts 02115
Boston, Massachusetts 02115
(617) 355-6000
Phone: 617-355-2668
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
Click here to add this to my saved trials